Comment
The app for independent voices
I don't think science can answer the question definitively. Is it really science to say that at 17 years and 364 days a procedure is ill-advised, but the next day it becomes acceptable?
I think she's trying to get to the right answer for the most people possible. She isn't abandoning the science. She is simply acknowledging its limitations on decisions that affect real people's lives.
These are decisions that need to be made by the people most intimately involved, especially the parents and hopef…
Well, no, we cannot agree that GAC is appropriate for some people. We simply don't know. And, that is the point of the story.
No long-term studies demonstrate that GAC for children and adolescents leads to better mental health outcomes. A recent comprehensive independent review of clinical studies commissioned by Florida (May 2022) found that the evidence in support of GAC was of “low” and “very low” certainty because of small sample sizes, biased samples, limited follow-up, and inconsistent out…
Clearly you have no expertise in this area.
WPATH has been around since 1979. They are the world's foremost authority on the subject. And they strongly disagree with the Cass Report. Their Standards of Care recommendations are thoroughly grounded in science.
Part of their public statement:
"In contrast to what the Cass Review recommends, WPATH and USPATH firmly stand
by the Standards of Care for the Health of Transgender and Gender Diverse People –
version 8, which was published in 2022—and based on far more systematic reviews
that the Cass Review—in collaboration with The School of Evidence-based Practice
Center at Johns Hopkins University and considers that the (research and consensusbased) evidence is such to recommend that providing medical treatment including
puberty-blocking medication and hormone therapy is helpful and often life-saving for
young TGD people, while withholding such treatment may lead to increased gender
dysphoria and adversely affect psychological functioning. Of note, many countries
have reacted critically regarding the Cass Review, disagreeing with its unfounded
medical opinion to severely limit the use of puberty-blocking medication and
hormone therapy for TGD young people. These countries include Canada, the
Netherlands, Belgium, Germany, Austria, Switzerland, and many states in the United
States. In Germany, a new guideline on adolescent transgender care has been
drafted (in collaboration with Austria and Switzerland) and is currently under review
by 27 professional societies. As drafted, this guideline does not restrict puberty
blockers and is in broad accordance with the WPATH SOC8 recommendations in its
adolescent chapter. The Cass Review appears to be an outlier, ignoring more than
three decades of clinical experience in this area as well as existing evidence showing
the benefits of hormonal interventions on the mental health and quality of life of
gender diverse young people (1-9)."